Trastuzumab-DM21
Trastuzumab-DM12 (T-DM21) is an antibody-drug conjugate (ADC). Trastuzumab-DM12 binds to HER2, inhibits HER2 shedding, and mediates antibody-dependent cellular cytotoxicity. Trastuzumab-DM12 is formed by conjugating the antibody Trastuzumab (HY-P9907) with DM-21 (HY-139441). Trastuzumab-DM12 can be used for cancer research.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
HER2 |
In Vitro
Antibody-drug conjugates (ADCs) are humanized or human monoclonal antibodies conjugated to highly cytotoxic small molecules (payloads) via chemical linkers. As a novel therapeutic modality, they hold great potential to drive a paradigm shift in cancer chemotherapy.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
SMILES
[Trastuzumab-DM21]
-
Synonyms
T-DM21
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Trastuzumab-DM21
- T-DM21
- Antibody-Drug Conjugates (ADCs)
- EGFR
- Antibody-Drug Conjugates
- ADC
- Epidermal growth factor receptor
- ErbB-1
- HER1
- lapatinib-resistant cancer cells
- HER2
- antibody-dependent cellular cytotoxicity
- trastuzumab-sensitive tumors
- trastuzumab-resistant tumors
- microtubule assembly
- cell death
- trastuzumab-resistant cancer cells
- Inhibitor
- inhibitor
- inhibit